Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:20 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer
NCT05328908 · Bristol-Myers Squibb · PHASE3 · terminated · last registry update 2026-08-26 · Colorectal cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, Bristol-Myers Squibb |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ABL1 in colorectal cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-03Also stopped (terminated): Peking University Cancer Hospital & Institute, KN046 + regorafenib (NCT05985109)
- 2026-09-11Results posted on the registry: Memorial Sloan Kettering Cancer Center, Regorafenib (NCT02023333)
- 2026-07-28Phase 3 first posted: Sichuan Baili Pharmaceutical Co., Ltd., BL-M07D1 + Regorafenib (NCT07730489)
- 2026-07-23Phase 3 first posted: Innovent Biologics (Suzhou) Co. Ltd., IBI363 + bevacizumab + Investigator's choice of therapy (NCT07722494)
- 2026-07-22Results posted on the registry: Amgen, Sotorasib + Panitumumab (NCT05198934)
- 2026-07-06Results posted on the registry: Syndax Pharmaceuticals, Revumenib + Chemotherapy (NCT05731947)
- 2026-07-06Also stopped (terminated): Syndax Pharmaceuticals, Revumenib + Chemotherapy (NCT05731947)
- 2026-06-16Results posted on the registry: University of Southern California, Pembrolizumab + Regorafenib (NCT03657641)
- 2026-05-29Results posted on the registry: National Cancer Institute (NCI), Paclitaxel + Nilotinib (NCT05185947)
- 2026-03-19Phase 3 first posted: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., TQB2102 Injection + Trifluridine /Tipiracil (TAS-102) tablets / Fruquintinib / Regorafenib tablets (NCT07483684)
- 2026-03-11Also stopped (withdrawn): M.D. Anderson Cancer Center, Regorafenib + Lorigerlimab (NCT07137390)
- 2026-02-25Also stopped (withdrawn): M.D. Anderson Cancer Center, Regorafenib + Lorigerlimab (NCT07223567)
- 2026-02-03Phase 3 first posted: Shanghai JMT-Bio Inc., JSKN003 + Physician choiced treatment, include: TAS-102, Regorafenib, Fruquintinib. (NCT07384377)
- 2026-01-20Also stopped (terminated): Anwaar Saeed, Regorafenib + Pembrolizumab (NCT06006923)
- 2025-12-03Results posted on the registry: Bristol-Myers Squibb, Nivolumab + Trametinib (NCT03377361)
- 2025-09-17Results posted on the registry: Merck Sharp & Dohme LLC, favezelimab/pembrolizumab + regorafenib (NCT05064059)
- 2025-09-17Results posted on the registry: Merck Sharp & Dohme LLC, favezelimab/pembrolizumab + regorafenib (NCT05600309)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision